The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.
paper
Cited
Public
Unavailable
- Authors
- Lichtman, A H; Martin, B R
- Year
- 1997
- Journal
- Pharmacology, biochemistry, and behavior
- PMID
- 9164547
- DOI
- 10.1016/s0091-3057(96)00121-9
The purported CB1 cannabinoid antagonist SR 141716A has proven to be a useful tool in the investigation of cannabinoid pharmacology. This antagonist was employed in the present study to investigate the antinociceptive and cataleptic effects of cannabinoids after either systemic or intracerebroventricular (ICV) administration. The antinociceptive potency of systemically administered delta 9-tetrahydrocannabinol (delta 9-THC) was decreased 18-fold by SR 141716A, from an ED50 value of 0.3-5.1 mg/kg. Similarly, it completely blocked the antinociceptive effects of delta 9-THC and CP 55,940, a potent bicyclic cannabinoid, after ICV administration. In addition, it prevented cannabinoid-induced catalepsy when given by either route of administration. In contrast, SR 141716A failed to antagonize the antinociceptive effects of morphine, indicating its selectivity for cannabinoid receptors. These findings indicate that the antinociceptive and cataleptic effects of delta 9-THC and CP 55,940 are mediated through CB1 cannabinoid receptors.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Delta-9-tetrahydrocannabinol and Cannabidiol for Pain: Preclinical and Clinical Models. | Harris HM et al. | β | 2026 | β |
| 2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice. | Morgan A et al. | β | 2022 | β |
| Assessment of dependence potential and abuse liability of Ξ<sup>8</sup>-tetrahydrocannabinol in mice. | Vanegas SO et al. | β | 2022 | β |
| Receptor mechanisms underlying the CNS effects of cannabinoids: CB<sub>1</sub> receptor and beyond. | Hempel B et al. | β | 2022 | β |
| Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases. | Haspula D et al. | β | 2020 | β |
| The Role of the Cannabinoid System in Opioid Analgesia and Tolerance. | Ozdemir E | β | 2020 | β |
| Cannabinoids and Pain: Sites and Mechanisms of Action. | Starowicz K et al. | β | 2017 | β |
| Genetic and Environmental Factors Associated with Cannabis Involvement. | Bogdan R et al. | β | 2016 | β |
| Roles for the endocannabinoid system in ethanol-motivated behavior. | Henderson-Redmond AN et al. | β | 2016 | β |
| CB1 cannabinoid receptor agonist inhibits matrix metalloproteinase activity in spinal cord injury: A possible mechanism of improved recovery. | Hong J et al. | β | 2015 | β |
| CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain. | Deng L et al. | β | 2015 | β |
| Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. | Carey CE et al. | β | 2015 | β |
| Neuropeptide VF Enhances Cannabinoid Agonist WIN55,212-2-Induced Antinociception in Mice. | Han ZL et al. | β | 2015 | β |
| The Role of the Brain's Endocannabinoid System in Pain and Its Modulation by Stress. | Corcoran L et al. | β | 2015 | β |
| Anandamide attenuates haloperidol-induced vacuous chewing movements in rats. | RΓΆpke J et al. | β | 2014 | β |
| Effects of repeated dosing with mechanistically distinct antinociceptive ligands in a rat model of neuropathic spinal cord injury pain. | Hama AT et al. | β | 2014 | β |
| The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. | Ghosh S et al. | β | 2013 | β |
| Involvement of descending serotonergic and noradrenergic pathways in CB1 receptor-mediated antinociception. | Dogrul A et al. | β | 2012 | β |
| Is there any clinically relevant cannabinoid-induced analgesia? | Kraft B | β | 2012 | β |
| Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat. | Craft RM et al. | β | 2012 | β |
| Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain. | Hama A et al. | β | 2011 | β |
| Antinociception and sedation following intracerebroventricular administration of ΞβΉ-tetrahydrocannabinol in female vs. male rats. | Wakley AA et al. | β | 2011 | β |
| Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception. | Hama A et al. | β | 2011 | β |
| Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain. | Sain NM et al. | β | 2009 | β |
| Physiological evidence of a postsynaptic inhibition of the tail flick reflex by a cannabinoid receptor agonist. | Dableh LJ et al. | β | 2009 | β |
| Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain. | Hama A et al. | β | 2009 | β |
| Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. | Sano K et al. | β | 2008 | β |
| CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist. | Hough LB et al. | β | 2007 | β |
| Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature. | Salussolia CL et al. | β | 2007 | β |
| On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). | Costa B | β | 2007 | β |
| Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. | Rea K et al. | β | 2007 | β |
| Effect of N-arachidonoyl-(2-methyl-4-hydroxyphenyl) amine (VDM11), an anandamide transporter inhibitor, on capsaicin-induced cough in mice. | Kamei J et al. | β | 2006 | β |
| Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. | Egashira N et al. | β | 2006 | β |
| Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. | Balerio GN et al. | β | 2006 | β |
| Cannabinoid function in learning, memory and plasticity. | Riedel G et al. | β | 2005 | β |
| Therapeutic potential of cannabinoid receptor agonists as analgesic agents. | Fox A et al. | β | 2005 | β |
| CB(1) receptor mediation of cannabinoid behavioral effects in male and female rats. | Tseng AH et al. | β | 2004 | β |
| Detection of cannabinoid agonist evoked increase in BOLD contrast in rats using functional magnetic resonance imaging. | Shah YB et al. | β | 2004 | β |
| Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. | Finn DP et al. | β | 2004 | β |
| Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. | Scott DA et al. | β | 2004 | β |
| Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. | Lichtman AH et al. | β | 2004 | β |
| Synergistic interactions between cannabinoid and opioid analgesics. | Cichewicz DL | β | 2004 | β |
| Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. | Finn DP et al. | β | 2003 | β |
| Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. | Ruiu S et al. | β | 2003 | β |
| The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. | Naef M et al. | β | 2003 | β |
| The effect of cannabinoid receptor antagonism with SR141716A on antinociception induced by cocaine and the NMDA receptor antagonist, MK-801. | Forman LJ | β | 2003 | β |
| The rodent amygdala contributes to the production of cannabinoid-induced antinociception. | Manning BH et al. | β | 2003 | β |
| Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. | Romero EM et al. | β | 2002 | β |
| CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. | Clayton N et al. | β | 2002 | β |
| Dynorphin-independent spinal cannabinoid antinociception. | Gardell LR et al. | β | 2002 | β |
| Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors. | Hough LB et al. | β | 2002 | β |
| Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids. | Janoyan JJ et al. | β | 2002 | β |
| Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice. | DeSanty KP et al. | β | 2001 | β |
| Cannabinoid receptors and pain. | Pertwee RG | β | 2001 | β |
| Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. | Fride E et al. | β | 2001 | β |
| Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse. | Azad SC et al. | β | 2001 | β |
| The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. | Darmani NA | β | 2001 | β |
| The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. | Fox A et al. | β | 2001 | β |
| Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. | Greenwald MK et al. | β | 2000 | β |
| Effects of the cannabinoid ligand SR 141716A alone or in combination with delta9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys. | Nakamura-Palacios EM et al. | β | 2000 | β |
| In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments. | Rubino T et al. | β | 2000 | β |
| Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. | Cosenza M et al. | β | 2000 | β |
| The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. | Burstein SH | β | 1999 | β |
| The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. | Li J et al. | β | 1999 | β |
| Brain cannabinoid systems as targets for the therapy of neurological disorders. | Consroe P | β | 1998 | β |
| Cannabinoid transmission and pain perception. | Martin BR et al. | β | 1998 | β |
| Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. | Lichtman AH et al. | β | 1998 | β |
| Watching the pot boil. | Fields HL et al. | β | 1998 | β |